Products
Treosulfan was approved in the EU in 2019 and in many countries in 2020 as a powder for the preparation of an infusion solution (Trecondi).
Structure and properties
Treosulfan (C6H14O8S2, Mr = 278.3 g/mol)
Effects
Treosulfan (ATC L01AB02) has cytotoxic and antineoplastic properties. It is a prodrug of a bifunctional alkylating agent active against hematopoietic progenitor cells. The drug target is DNA, in which cross-links are induced.
Indications
In combination with fludarabine as part of conditioning therapy before allogeneic hematopoietic stem cell transplantation in adult patients with malignant and nonmalignant disease and in malignant disease in children and adolescents older than 1 month.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include: